Exclusive Interview with Dr. Guy Miller, CEO of Edison Pharma.
Is there hope for a cure for Mitochondrial Disease? Perhaps the answer is closer than we thought.
On July 15, 2008 Edison Pharma and partner Penwest Pharmaceuticals announced that A0001, an “improved” variant of Coenzyme Q10 (CoQ10), has entered Phase 1 clinical development with healthy volunteers. Edison predicts trials in patients with inherited mitochondrial disease will begin in 2009.
Becoming a great advocate: advice for complex patients and families, with Mark Korson MD and Maggie Orr RN Adult patients, caregivers, parents of affected...
Mitochondrial Augmentation Technology (MAT) involves internalizing healthy, functional mitochondria into patient-derived cells to address mitochondrial dysfunction. Minovia has developed two generations of MAT products,...